Literature DB >> 29285342

A study on the predictability of acute lymphoblastic leukaemia response to treatment using a hybrid oncosimulator.

Eleftherios Ouzounoglou1, Eleni Kolokotroni1, Martin Stanulla2, Georgios S Stamatakos1.   

Abstract

Efficient use of Virtual Physiological Human (VPH)-type models for personalized treatment response prediction purposes requires a precise model parameterization. In the case where the available personalized data are not sufficient to fully determine the parameter values, an appropriate prediction task may be followed. This study, a hybrid combination of computational optimization and machine learning methods with an already developed mechanistic model called the acute lymphoblastic leukaemia (ALL) Oncosimulator which simulates ALL progression and treatment response is presented. These methods are used in order for the parameters of the model to be estimated for retrospective cases and to be predicted for prospective ones. The parameter value prediction is based on a regression model trained on retrospective cases. The proposed Hybrid ALL Oncosimulator system has been evaluated when predicting the pre-phase treatment outcome in ALL. This has been correctly achieved for a significant percentage of patient cases tested (approx. 70% of patients). Moreover, the system is capable of denying the classification of cases for which the results are not trustworthy enough. In that case, potentially misleading predictions for a number of patients are avoided, while the classification accuracy for the remaining patient cases further increases. The results obtained are particularly encouraging regarding the soundness of the proposed methodologies and their relevance to the process of achieving clinical applicability of the proposed Hybrid ALL Oncosimulator system and VPH models in general.

Entities:  

Keywords:  acute lymphoblastic leukaemia; machine learning methods; multiscale modelling; oncosimulator; prednisone response prediction; simulation model

Year:  2017        PMID: 29285342      PMCID: PMC5740218          DOI: 10.1098/rsfs.2016.0163

Source DB:  PubMed          Journal:  Interface Focus        ISSN: 2042-8898            Impact factor:   3.906


  40 in total

1.  Missing value estimation methods for DNA microarrays.

Authors:  O Troyanskaya; M Cantor; G Sherlock; P Brown; T Hastie; R Tibshirani; D Botstein; R B Altman
Journal:  Bioinformatics       Date:  2001-06       Impact factor: 6.937

2.  Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia.

Authors:  Gunnar Cario; Martin Stanulla; Bernard M Fine; Oliver Teuffel; Nils V Neuhoff; André Schrauder; Thomas Flohr; Beat W Schäfer; Claus R Bartram; Karl Welte; Brigitte Schlegelberger; Martin Schrappe
Journal:  Blood       Date:  2004-09-23       Impact factor: 22.113

3.  Cell division rates of primary human precursor B cells in culture reflect in vivo rates.

Authors:  Jonathan Cooperman; Robert Neely; David T Teachey; Stephen Grupp; John Kim Choi
Journal:  Stem Cells       Date:  2004       Impact factor: 6.277

4.  DNA microarray data imputation and significance analysis of differential expression.

Authors:  Rebecka Jörnsten; Hui-Yu Wang; William J Welsh; Ming Ouyang
Journal:  Bioinformatics       Date:  2005-08-23       Impact factor: 6.937

5.  Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia.

Authors:  M Dördelmann; A Reiter; A Borkhardt; W D Ludwig; N Götz; S Viehmann; H Gadner; H Riehm; M Schrappe
Journal:  Blood       Date:  1999-08-15       Impact factor: 22.113

6.  Cell cycle analysis in lymphoid neoplasia of childhood: differences among immunologic subtypes and similarities in the proliferation of normal and leukaemic precursor B cells.

Authors:  A Hirt; E M Werren; A R Luethy; J Gerdes; H P Wagner
Journal:  Br J Haematol       Date:  1992-02       Impact factor: 6.998

7.  In childhood acute lymphoblastic leukemia the hypophosphorylated retinoblastoma protein, p110RB, is diminished, as compared with normal CD34+ peripheral blood progenitor cells.

Authors:  K Leibundgut; N Schmitz; A Tobler; A R Lüthy; A Hirt
Journal:  Pediatr Res       Date:  1999-05       Impact factor: 3.756

8.  Cell-cycle-associated expressions of proliferating cell nuclear antigen and Ki-67 reactive antigen of bone marrow blast cells in childhood acute leukemia.

Authors:  M Tsurusawa; M Ito; Z Zha; S Kawai; Y Takasaki; T Fujimoto
Journal:  Leukemia       Date:  1992-07       Impact factor: 11.528

9.  The "Oncosimulator": a multilevel, clinically oriented simulation system of tumor growth and organism response to therapeutic schemes. Towards the clinical evaluation of in silico oncology.

Authors:  Georgios S Stamatakos; Dimitra D Dionysiou; Norbert M Graf; Nikoletta A Sofra; Christine Desmedt; Alexander Hoppe; Nikolaos K Uzunoglu; Manolis Tsiknakis
Journal:  Conf Proc IEEE Eng Med Biol Soc       Date:  2007

10.  Which missing value imputation method to use in expression profiles: a comparative study and two selection schemes.

Authors:  Guy N Brock; John R Shaffer; Richard E Blakesley; Meredith J Lotz; George C Tseng
Journal:  BMC Bioinformatics       Date:  2008-01-10       Impact factor: 3.169

View more
  2 in total

Review 1.  The case for AI-driven cancer clinical trials - The efficacy arm in silico.

Authors:  Likhitha Kolla; Fred K Gruber; Omar Khalid; Colin Hill; Ravi B Parikh
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2021-05-31       Impact factor: 11.414

Review 2.  Navigating Multi-Scale Cancer Systems Biology Towards Model-Driven Clinical Oncology and Its Applications in Personalized Therapeutics.

Authors:  Mahnoor Naseer Gondal; Safee Ullah Chaudhary
Journal:  Front Oncol       Date:  2021-11-24       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.